Modelling of optimal vaccination strategies in response to a bioterrorism associated smallpox outbreak.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
04 03 2021
Historique:
entrez: 18 3 2021
pubmed: 19 3 2021
medline: 24 6 2021
Statut: ppublish

Résumé

The reemergence of smallpox as a bioterrorism attack is now an increasing and legitimate concern. Advances in synthetic biology have now made it possible for the virus to be synthesized in a laboratory, with methods publicly available. Smallpox introduction into a susceptible population, with increased immunosuppression and an aging population, raises questions of how vaccination should be used in an epidemic situation when supply may be limited. We constructed three modified susceptible-latent-infectious-recovered (SEIR) models to simulate targeted, ring and mass vaccination in response to a smallpox outbreak in Sydney, Australia. We used age-specific distributions of susceptibility, infectivity, contact rates, and tested outputs under different assumptions. The number of doses needed of second- and third-generation vaccines are estimated, along with the total number of deaths at the end of the epidemic. We found a faster response is the key and ring vaccination of traced contacts is the most effective strategy and requires a smaller number of doses. However if public health authorities are unable to trace a high proportion of contacts, mass vaccination with at least 125,000 doses delivered per day is required. This study informs a better preparedness and response planning for vaccination in a case of a smallpox outbreak in a setting such as Sydney.

Identifiants

pubmed: 33734944
doi: 10.1080/21645515.2020.1800324
pmc: PMC7993194
doi:

Substances chimiques

Smallpox Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

738-746

Références

Lancet Infect Dis. 2015 Mar;15(3):340-7
pubmed: 25661473
Emerg Infect Dis. 2018 Apr;24(4):646-653
pubmed: 29553311
Vaccine. 2013 Oct 25;31(45):5192-201
pubmed: 23994378
MMWR Morb Mortal Wkly Rep. 2015 Feb 13;64(5):121-3
pubmed: 25674993
Environ Health Prev Med. 2011 Sep;16(5):281-9
pubmed: 21431786
Drug Des Devel Ther. 2010 May 25;4:71-9
pubmed: 20531961
Epidemiol Infect. 2004 Jan;132(1):19-25
pubmed: 14979585
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10935-40
pubmed: 12118122
Epidemiol Infect. 2014 Sep;142(9):1802-8
pubmed: 24308554
PLoS One. 2019 Jun 14;14(6):e0217704
pubmed: 31199825
Emerg Infect Dis. 2004 May;10(5):832-41
pubmed: 15200816
Science. 2002 Nov 15;298(5597):1428-32
pubmed: 12434061
Nature. 2001 Dec 13;414(6865):748-51
pubmed: 11742399
Med Decis Making. 2011 Jan-Feb;31(1):69-78
pubmed: 20484093
Travel Med Infect Dis. 2017 May - Jun;17:69-70
pubmed: 28545976
BMC Public Health. 2004 Aug 06;4:34
pubmed: 15298713
Science. 2015 Mar 13;347(6227):aaa4339
pubmed: 25766240
Int J Environ Res Public Health. 2016 Feb 24;13(3):
pubmed: 26927140
Nature. 2004 May 13;429(6988):180-4
pubmed: 15141212
Influenza Other Respir Viruses. 2017 Nov;11(6):511-517
pubmed: 28799710
Osong Public Health Res Perspect. 2015 Aug;6(4):269-78
pubmed: 26473095
Epidemiol Infect. 2007 Oct;135(7):1133-44
pubmed: 17222358
Health Secur. 2017 Nov/Dec;15(6):620-628
pubmed: 28836863
Clin Microbiol Infect. 2013 Nov;19(11):999-1005
pubmed: 24266045
Bull World Health Organ. 1973 May;48(5):517-22
pubmed: 4359678
Clin Infect Dis. 2019 Jun 18;69(1):159-166
pubmed: 30383204
J Infect Chemother. 2005 Apr;11(2):71-80
pubmed: 15856374
Environ Health Prev Med. 2010 Mar;15(2):84-93
pubmed: 19784718
Math Biosci. 2005 Jun;195(2):228-51
pubmed: 15913667
Mil Med. 2018 Jul 1;183(7-8):e200-e207
pubmed: 29425329
J Infect Dis. 1972 Feb;125(2):161-9
pubmed: 5007552
Int J Infect Dis. 2007 Mar;11(2):98-108
pubmed: 16899385
Euro Surveill. 2014 Oct 09;19(40):20920
pubmed: 25323076
Am J Epidemiol. 2003 Jul 15;158(2):110-7
pubmed: 12851223
Disaster Med Public Health Prep. 2012 Oct;6(3):270-6
pubmed: 23077270
Math Biosci. 2003 Sep;185(1):33-72
pubmed: 12900141
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
J Infect Dis. 2003 Oct 1;188(7):973-6
pubmed: 14513416
MMWR Recomm Rep. 2015 Feb 20;64(RR-02):1-26
pubmed: 25695372

Auteurs

Valentina Costantino (V)

Biosecurity Program, Kirby Institute, Faculty of Medicine, The University of New South Wales, Sydney, Australia.

Mohana Kunasekaran (M)

Biosecurity Program, Kirby Institute, Faculty of Medicine, The University of New South Wales, Sydney, Australia.

Chandini Raina MacIntyre (CR)

Biosecurity Program, Kirby Institute, Faculty of Medicine, The University of New South Wales, Sydney, Australia.
College of Public Service and Community Solutions, Arizona State University, Arizona, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH